# Topotecan in Treating Patients With Recurrent Brain Tumors

> **NCT00003372** · PHASE2 · COMPLETED · sponsor: **NCIC Clinical Trials Group** · enrollment: 17 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00003372
- **Lead sponsor:** NCIC Clinical Trials Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1997-12-08
- **Primary completion:** 2000-10-05
- **Final completion:** 2009-12-21
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2020-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003372, "Topotecan in Treating Patients With Recurrent Brain Tumors". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00003372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*